[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CR20230566A - Derivados de triazina y su uso en el tratamiento del cáncer - Google Patents

Derivados de triazina y su uso en el tratamiento del cáncer

Info

Publication number
CR20230566A
CR20230566A CR20230566A CR20230566A CR20230566A CR 20230566 A CR20230566 A CR 20230566A CR 20230566 A CR20230566 A CR 20230566A CR 20230566 A CR20230566 A CR 20230566A CR 20230566 A CR20230566 A CR 20230566A
Authority
CR
Costa Rica
Prior art keywords
sup
cancer
treatment
triazine derivatives
compounds
Prior art date
Application number
CR20230566A
Other languages
English (en)
Inventor
Andreas Michael Tosstorff
Georg Jaeschke
Stefanie Katharina Mesch
Christian Schnider
Sandra Steiner
Lea Aurelie Bouche
Wolfgang Guba
Angélique Patiny-Adam
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20230566A publication Critical patent/CR20230566A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D253/00Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/061,2,4-Triazines
    • C07D253/0651,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/071,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención se refiere a compuestos novedosos que tienen la fórmula general Ib, en donde R1, R2, R3, R4, R5 y Z son como se describen en la presente, una composición que incluye los compuestos y métodos para usar los compuestos.
CR20230566A 2021-06-04 2022-06-02 Derivados de triazina y su uso en el tratamiento del cáncer CR20230566A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP21177660 2021-06-04
EP21188639 2021-07-30
EP21215875 2021-12-20
PCT/EP2022/064995 WO2022253936A1 (en) 2021-06-04 2022-06-02 Triazine derivatives and their use in the treatment of cancer.

Publications (1)

Publication Number Publication Date
CR20230566A true CR20230566A (es) 2024-01-22

Family

ID=82115763

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230566A CR20230566A (es) 2021-06-04 2022-06-02 Derivados de triazina y su uso en el tratamiento del cáncer

Country Status (16)

Country Link
US (1) US20240132471A1 (es)
EP (1) EP4347571A1 (es)
JP (1) JP2024522494A (es)
KR (1) KR20240019083A (es)
AR (1) AR126053A1 (es)
AU (1) AU2022287224A1 (es)
BR (1) BR112023025318A2 (es)
CA (1) CA3216026A1 (es)
CL (1) CL2023003491A1 (es)
CO (1) CO2023016212A2 (es)
CR (1) CR20230566A (es)
IL (1) IL307201A (es)
MX (1) MX2023013998A (es)
PE (1) PE20240928A1 (es)
TW (1) TW202313577A (es)
WO (1) WO2022253936A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
TW202327604A (zh) * 2022-01-07 2023-07-16 大陸商藥捷安康(南京)科技股份有限公司 Nlrp3發炎小體抑制劑及其應用
WO2024017924A1 (en) * 2022-07-21 2024-01-25 F. Hoffmann-La Roche Ag Nlrp3 inhibitors
WO2024094185A1 (zh) * 2022-11-04 2024-05-10 药捷安康(南京)科技股份有限公司 Nlrp3炎症小体抑制剂及其应用
WO2024121086A1 (en) * 2022-12-07 2024-06-13 F. Hoffmann-La Roche Ag Novel compounds as modulators of nlrp3 inhibition
WO2024193541A1 (en) * 2023-03-20 2024-09-26 Insilico Medicine Ip Limited Nlrp3 inflammasome inhibitors and uses thereof
WO2024193699A1 (zh) * 2023-03-23 2024-09-26 成都赜灵生物医药科技有限公司 三嗪类化合物及其用途
WO2024218100A1 (en) * 2023-04-19 2024-10-24 F. Hoffmann-La Roche Ag Oxazolo[4,5-b]pyrazine and oxazolo[4,5-b]pyridine derivatives as nlrp3 inhibitors for the treatment of e.g. inflammatory diseases
WO2024218188A1 (en) * 2023-04-19 2024-10-24 F. Hoffmann-La Roche Ag 5-[5-(2-hydroxyphenyl)oxazolo[4,5-b]pyridin-2-yl]piperidin-2-one derivatives as nlpr3 inhibitors for the treatment of inflammatory diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3920917A4 (en) * 2019-02-04 2022-09-28 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATION OF SPLICING
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
CA3167023A1 (en) 2020-01-22 2021-07-29 F. Hoffmann-La Roche Ag Sulfonimidamide compounds as nlrp3 modulators

Also Published As

Publication number Publication date
IL307201A (en) 2023-11-01
WO2022253936A1 (en) 2022-12-08
PE20240928A1 (es) 2024-04-30
AR126053A1 (es) 2023-09-06
CA3216026A1 (en) 2022-12-08
CO2023016212A2 (es) 2023-12-11
MX2023013998A (es) 2023-12-11
KR20240019083A (ko) 2024-02-14
TW202313577A (zh) 2023-04-01
JP2024522494A (ja) 2024-06-21
AU2022287224A1 (en) 2023-09-21
US20240132471A1 (en) 2024-04-25
CL2023003491A1 (es) 2024-05-24
BR112023025318A2 (pt) 2024-02-27
EP4347571A1 (en) 2024-04-10

Similar Documents

Publication Publication Date Title
CR20230566A (es) Derivados de triazina y su uso en el tratamiento del cáncer
MX2021011209A (es) Novedosos inhibidores de molécula pequeña de factores de transcripción tead.
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
EP4374858A3 (en) Benzimidazolone derived inhibitors of bcl6
TW200745004A (en) Novel compounds, their preparation and use
MX2023012907A (es) Inhibidores de inflamasoma proteina 3 que contiene dominios de pirina (nlrp3).
ZA202201364B (en) Deuterated compounds for use in the treatment of cancer
CY1109906T1 (el) Παραγωγα c3-kyano εποθιλονης
EP4371562A3 (en) 2-quinolone derived inhibitors of bcl6
PH12021550382A1 (en) Tetrahydropyridopyrimidine derivatives as ahr modulators
MX2010003365A (es) Derivados de tiazol para el tratamiento de cancer.
CR20230382A (es) Derivados de tetrahidroazepina bicíclicos para el tratamiento del cáncer
TW200630374A (en) Thiazolyldihydroindazoles
CR20230410A (es) Derivados novedosos de pirimidin-2-il-sulfonamida
CR20210460A (es) Compuestos útiles en la terapia del vih
EP4233865A3 (en) Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers
MX2020008746A (es) Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado.
MX2023011715A (es) Compuestos de oxoisoindolina sustituidos con piridinilo.
MX2021009426A (es) Derivados de indazolil-isoxazol para el tratamiento de enfermedades tales como cancer.
WO2023107574A3 (en) Lipid-based compositions and methods thereof
MX2024002409A (es) Terapias contra el cancer.
MX2022011646A (es) Celulas t v delta1+ para el tratamiento de neoplasias mieloides.
MXPA03005374A (es) Carbazoles antitumorales.
MX2024003028A (es) Derivados de 6 aza quinolina y usos relacionados.
WO2023049808A3 (en) Small molecule inhibitors of tead-yap